Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01156311
What this trial is testing

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Biogen 108
Not applicableLooking for participantsNCT05958381
What this trial is testing

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
The University of Texas at Dallas 100
Not applicableStudy completedNCT03134573
What this trial is testing

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

Who this might be right for
Multiple Sclerosis
Bayer 96
Post-approval studies (Phase 4)Study completedNCT03385356
What this trial is testing

Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingVitamin D Deficiency
University Medical Centre Maribor 89
Early research (Phase 1)Study completedNCT01466322
What this trial is testing

Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GlaxoSmithKline 16
Not applicableStudy completedNCT03539094
What this trial is testing

Intermittent Fasting in Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Washington University School of Medicine 61
Post-approval studies (Phase 4)Ended earlyNCT00574041
What this trial is testing

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 19
Not applicableActive Not RecruitingNCT06345157
What this trial is testing

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Novartis Pharmaceuticals 379
Post-approval studies (Phase 4)Study completedNCT02090413
What this trial is testing

Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 241
Not applicableStudy completedNCT02549703
What this trial is testing

Mitochondrial Dysfunction and Disease Progression

Who this might be right for
Clinically Isolated SyndromeRelapsing-Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis+1 more
Icahn School of Medicine at Mount Sinai 47
Testing effectiveness (Phase 2)UnknownNCT05417269
What this trial is testing

IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Imcyse SA 150
Testing effectiveness (Phase 2)Study completedNCT00050778
What this trial is testing

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genzyme, a Sanofi Company 334
Large-scale testing (Phase 3)Looking for participantsNCT05906992
What this trial is testing

Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Celltrion 512
Large-scale testing (Phase 3)Study completedNCT00211887
What this trial is testing

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Fred Lublin 1,008
Testing effectiveness (Phase 2)Study completedNCT00640328
What this trial is testing

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

Who this might be right for
Multiple Sclerosis
GlaxoSmithKline 38
Early research (Phase 1)Study completedNCT01738347
What this trial is testing

Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

Who this might be right for
Relapsing-remitting Multiple Sclerosis (rrMS)
GE Healthcare 30
Post-approval studies (Phase 4)Study completedNCT00206648
What this trial is testing

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bayer 271
Testing effectiveness (Phase 2)Study completedNCT01416155
What this trial is testing

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Biogen 97
Testing effectiveness (Phase 2)Study completedNCT00893217
What this trial is testing

BEYOND Pilot Study

Who this might be right for
Multiple SclerosisRelapsing-Remitting
Bayer 71
Not applicableStudy completedNCT03561402
What this trial is testing

Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
McGill University 24
Next Page